Iterum Therapeutics plc
764.9M
$3.96M
-1.41
$-1.26
No price alerts set. Add an alert to get notified!
-1.41
-8.54
$-1.26
607.06%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ANTX
AN2 Therapeutics, Inc.
|
$3.49 | -4.64% | -3.00 | $94.26M | 0.00 |
|
BOLD
Boundless Bio, Inc.
|
$1.08 | -3.15% | -0.41 | $24.09M | 0.50 |
|
IBIO
iBio, Inc.
|
$1.73 | -1.99% | -6.91 | $27.24M | 0.04 |
|
INTS
Intensity Therapeutics, Inc.
|
$5.79 | -3.18% | -6.77 | $10.92M | 0.01 |
|
KLTO
Klotho Neurosciences, Inc.
|
$0.38 | -7.10% | - | $20.08M | - |
|
PLUR
Pluri Inc.
|
$3.32 | 2.47% | -1.18 | $27.30M | -2.79 |
|
QTTB
Q32 Bio Inc.
|
$5.94 | -18.05% | 2.50 | $72.44M | 0.27 |
|
RLYB
Rallybio Corporation
|
$7.91 | -3.77% | -4.65 | $42.08M | 0.00 |
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
|
$1.26 | -59.35% | -0.32 | $8.43M | 0.00 |
|
TAOX
TAO Synergies Inc.
|
$5.38 | 3.07% | -0.52 | $18.76M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$1.50
$0.06
$0.00
0.00%
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
